Cargando…
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
PURPOSE: After nearly 3 years of the COVID-19 pandemic, even though a vast body of knowledge and products (including vaccines and treatments) have been developed and disseminated, the virus is still evolving and new variants arising. Consequently, thousands of lives continue to be lost. Neutralizing...
Autores principales: | de Almeida Oliveira, Aline, Praia Borges Freire, Diana, Rodrigues de Andrade, Ana, de Miranda Marques, Amanda, da Silva Madeira, Luciana, Moreno Senna, José Procópio, Freitas Brasileiro da Silveira, Ivna Alana, de Castro Fialho, Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943047/ https://www.ncbi.nlm.nih.gov/pubmed/36843665 http://dx.doi.org/10.1007/s12247-023-09713-w |
Ejemplares similares
-
‘nAb’ the self-reactive activity in the COVID-19 combat
por: Narasimhan, Madhusudhanan, et al.
Publicado: (2021) -
Surrogate test performance for SARS‐CoV‐2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
por: Wendel, Silvano, et al.
Publicado: (2021) -
Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections
por: Saraiva, Felipe Betoni, et al.
Publicado: (2019) -
Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021) -
Resistance exercise with different volumes: blood pressure response and forearm blood flow in the hypertensive elderly
por: Brito, Aline de Freitas, et al.
Publicado: (2014)